Category Archives: Global

UK Postpones Decision on Value-Based Assessment — Again

By Leela Barham. Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).  The general concept of VBP was to set almost provisional prices based on the expected value of new medicines using immature data, with provisions to ‘correct’ the price […]
Also posted in Europe, Guest Blog, Op-Ed, pricing | Tagged , , , , , , | Leave a comment

EMA Calls Out to Companies Developing Ebola Treatments

The European Medicines Agency (EMA) is reviewing available information on Ebola treatments currently under development to “facilitate evidence-based decision-making” by health authorities. At the moment there are no approved medicines to protect from or treat Ebola. Some experimental treatments have reportedly shown encouraging results in the laboratory or in animals, but they have not yet […]
Also posted in Europe, healthcare, Regulatory | Tagged , , | Leave a comment

EFPIA Promises Stronger Ties with China

The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”. Federation delegates are this week concluding a visit to Beijing to establish “a better understanding of the numerous healthcare reforms underway in China … and explore closer paths of cooperation in global drug development between China and […]
Also posted in Europe, Events, Regulatory | Tagged , , , | Leave a comment

Japan’s Non-Hodgkin Lymphoma Market to Top $1 Billion by 2020

The Non-Hodgkin Lymphoma (NHL) treatment market in the Asia-Pacific (APAC) countries of India, Australia, China and Japan will expand from $1.1 billion in 2013 to $1.7 billion by 2020, with Japan remaining the largest contributor to growth, according to GBI Research. The company’s new report says that Japan had a 67.2% share of the APAC […]
Also posted in healthcare | Tagged , , , , , , | Leave a comment

What's the Future of European Health Policy?

What can be gleaned about the direction that health policy will take for the next five years under the new European Commission, scheduled to take office at the beginning of November? Peter O’ Donnell address this question in his new Applied Clinical Trials column here.
Also posted in Europe, Guest Blog, healthcare, Op-Ed, Regulatory | Tagged , , | Leave a comment
  • Categories

  • Meta